GlassScriptPhysician profile
Isabel D Goncalves
NPI 1740378736
$1,208.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $123 · 2021: $386 · 2022: $322.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.31 | 2019-2022 | |
| Astellas Pharma US INC | $163.92 | 2019-2021 | |
| Lupin INC. | $116.97 | 2019-2020 | |
| Agile Therapeutics, INC. | $85.22 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $80.13 | 2021-2022 | |
| Allergan, INC. | $69.26 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $62.21 | 2021 | |
| Therapeuticsmd, INC. | $49.33 | 2019-2021 | |
| Exeltis, USA INC. | $42.58 | 2019-2022 | |
| Myovant Sciences INC. | $39.72 | 2021 | |
| Merck Sharp & Dohme LLC | $27.48 | 2019-2020 | |
| Urovant Sciences INC | $22.61 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2022 | |
| Medicem INC. | $15.74 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $14.27 | 2022 | |
| Pfizer INC. | $12.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Goncalves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.